nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—ORM1—Vemurafenib—melanoma	0.208	0.436	CbGbCtD
Canagliflozin—ALB—melanoma	0.188	0.512	CbGaD
Canagliflozin—ABCB1—melanoma	0.179	0.488	CbGaD
Canagliflozin—ALB—Vemurafenib—melanoma	0.0875	0.184	CbGbCtD
Canagliflozin—CYP3A4—Temozolomide—melanoma	0.05	0.105	CbGbCtD
Canagliflozin—ABCC2—Docetaxel—melanoma	0.0482	0.101	CbGbCtD
Canagliflozin—ABCB1—Dactinomycin—melanoma	0.0304	0.0638	CbGbCtD
Canagliflozin—CYP3A4—Vemurafenib—melanoma	0.0274	0.0575	CbGbCtD
Canagliflozin—ABCB1—Docetaxel—melanoma	0.0157	0.0329	CbGbCtD
Canagliflozin—CYP3A4—Docetaxel—melanoma	0.00941	0.0197	CbGbCtD
Canagliflozin—Sunburn—Vemurafenib—melanoma	0.00501	0.0899	CcSEcCtD
Canagliflozin—Rash papular—Vemurafenib—melanoma	0.00406	0.0729	CcSEcCtD
Canagliflozin—Rash generalised—Vemurafenib—melanoma	0.00356	0.0639	CcSEcCtD
Canagliflozin—Rash maculo-papular—Vemurafenib—melanoma	0.00138	0.0247	CcSEcCtD
Canagliflozin—Photosensitivity—Vemurafenib—melanoma	0.00125	0.0225	CcSEcCtD
Canagliflozin—Rash generalised—Docetaxel—melanoma	0.00121	0.0217	CcSEcCtD
Canagliflozin—Prurigo—Docetaxel—melanoma	0.00111	0.02	CcSEcCtD
Canagliflozin—Cystitis noninfective—Bleomycin—melanoma	0.000896	0.0161	CcSEcCtD
Canagliflozin—Cystitis—Bleomycin—melanoma	0.000885	0.0159	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Vemurafenib—melanoma	0.000867	0.0156	CcSEcCtD
Canagliflozin—Bladder pain—Bleomycin—melanoma	0.000829	0.0149	CcSEcCtD
Canagliflozin—Vaginal infection—Temozolomide—melanoma	0.00073	0.0131	CcSEcCtD
Canagliflozin—Dapagliflozin—ABCB1—melanoma	0.000702	1	CrCbGaD
Canagliflozin—Angiopathy—Vemurafenib—melanoma	0.00069	0.0124	CcSEcCtD
Canagliflozin—Rash erythematous—Docetaxel—melanoma	0.000672	0.0121	CcSEcCtD
Canagliflozin—Diabetes mellitus—Carmustine—melanoma	0.000668	0.012	CcSEcCtD
Canagliflozin—Malnutrition—Vemurafenib—melanoma	0.000662	0.0119	CcSEcCtD
Canagliflozin—Erythema—Vemurafenib—melanoma	0.000662	0.0119	CcSEcCtD
Canagliflozin—Thirst—Temozolomide—melanoma	0.00059	0.0106	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.000559	0.01	CcSEcCtD
Canagliflozin—Infection—Vemurafenib—melanoma	0.000536	0.00963	CcSEcCtD
Canagliflozin—Nervous system disorder—Vemurafenib—melanoma	0.00053	0.0095	CcSEcCtD
Canagliflozin—Skin disorder—Vemurafenib—melanoma	0.000524	0.00941	CcSEcCtD
Canagliflozin—Dehydration—Temozolomide—melanoma	0.000522	0.00937	CcSEcCtD
Canagliflozin—Breast disorder—Temozolomide—melanoma	0.000507	0.00911	CcSEcCtD
Canagliflozin—Hypotension—Vemurafenib—melanoma	0.000505	0.00905	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Vemurafenib—melanoma	0.000466	0.00837	CcSEcCtD
Canagliflozin—Fatigue—Vemurafenib—melanoma	0.000466	0.00835	CcSEcCtD
Canagliflozin—Constipation—Vemurafenib—melanoma	0.000462	0.00829	CcSEcCtD
Canagliflozin—Pollakiuria—Temozolomide—melanoma	0.000448	0.00804	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Temozolomide—melanoma	0.000443	0.00795	CcSEcCtD
Canagliflozin—Urinary tract infection—Carmustine—melanoma	0.000435	0.00781	CcSEcCtD
Canagliflozin—Urinary tract infection—Temozolomide—melanoma	0.000421	0.00755	CcSEcCtD
Canagliflozin—Erythema—Bleomycin—melanoma	0.000401	0.00719	CcSEcCtD
Canagliflozin—Hypersensitivity—Vemurafenib—melanoma	0.000398	0.00714	CcSEcCtD
Canagliflozin—Asthenia—Vemurafenib—melanoma	0.000387	0.00695	CcSEcCtD
Canagliflozin—Urinary tract disorder—Temozolomide—melanoma	0.000384	0.00688	CcSEcCtD
Canagliflozin—Pruritus—Vemurafenib—melanoma	0.000382	0.00686	CcSEcCtD
Canagliflozin—Urethral disorder—Temozolomide—melanoma	0.000381	0.00683	CcSEcCtD
Canagliflozin—Erythema—Dactinomycin—melanoma	0.000374	0.00671	CcSEcCtD
Canagliflozin—Dizziness—Vemurafenib—melanoma	0.000357	0.00641	CcSEcCtD
Canagliflozin—Angiopathy—Temozolomide—melanoma	0.000352	0.00632	CcSEcCtD
Canagliflozin—Erythema—Carmustine—melanoma	0.00035	0.00628	CcSEcCtD
Canagliflozin—Malnutrition—Carmustine—melanoma	0.00035	0.00628	CcSEcCtD
Canagliflozin—Dehydration—Docetaxel—melanoma	0.000347	0.00623	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Docetaxel—melanoma	0.000341	0.00612	CcSEcCtD
Canagliflozin—Rash—Vemurafenib—melanoma	0.00034	0.00611	CcSEcCtD
Canagliflozin—Dermatitis—Vemurafenib—melanoma	0.00034	0.0061	CcSEcCtD
Canagliflozin—Malnutrition—Temozolomide—melanoma	0.000338	0.00607	CcSEcCtD
Canagliflozin—Erythema—Temozolomide—melanoma	0.000338	0.00607	CcSEcCtD
Canagliflozin—Breast disorder—Docetaxel—melanoma	0.000337	0.00606	CcSEcCtD
Canagliflozin—Infection—Bleomycin—melanoma	0.000325	0.00583	CcSEcCtD
Canagliflozin—Nausea—Vemurafenib—melanoma	0.000321	0.00576	CcSEcCtD
Canagliflozin—Angioedema—Temozolomide—melanoma	0.000309	0.00554	CcSEcCtD
Canagliflozin—Hypotension—Bleomycin—melanoma	0.000306	0.00549	CcSEcCtD
Canagliflozin—Convulsion—Carmustine—melanoma	0.000303	0.00544	CcSEcCtD
Canagliflozin—Infection—Dactinomycin—melanoma	0.000303	0.00544	CcSEcCtD
Canagliflozin—Convulsion—Temozolomide—melanoma	0.000293	0.00526	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000286	0.00513	CcSEcCtD
Canagliflozin—Infection—Carmustine—melanoma	0.000284	0.00509	CcSEcCtD
Canagliflozin—Dry mouth—Temozolomide—melanoma	0.000282	0.00505	CcSEcCtD
Canagliflozin—Infection—Temozolomide—melanoma	0.000274	0.00492	CcSEcCtD
Canagliflozin—Nervous system disorder—Temozolomide—melanoma	0.000271	0.00486	CcSEcCtD
Canagliflozin—Skin disorder—Temozolomide—melanoma	0.000268	0.00481	CcSEcCtD
Canagliflozin—Hypotension—Carmustine—melanoma	0.000267	0.00479	CcSEcCtD
Canagliflozin—Fatigue—Dactinomycin—melanoma	0.000263	0.00472	CcSEcCtD
Canagliflozin—Urticaria—Bleomycin—melanoma	0.00026	0.00466	CcSEcCtD
Canagliflozin—Urinary tract disorder—Docetaxel—melanoma	0.000255	0.00458	CcSEcCtD
Canagliflozin—Urethral disorder—Docetaxel—melanoma	0.000253	0.00454	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Dactinomycin—melanoma	0.000249	0.00448	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Carmustine—melanoma	0.000247	0.00442	CcSEcCtD
Canagliflozin—Constipation—Carmustine—melanoma	0.000244	0.00438	CcSEcCtD
Canagliflozin—Abdominal pain—Dactinomycin—melanoma	0.000241	0.00433	CcSEcCtD
Canagliflozin—Hypersensitivity—Bleomycin—melanoma	0.000241	0.00433	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Temozolomide—melanoma	0.000238	0.00428	CcSEcCtD
Canagliflozin—Fatigue—Temozolomide—melanoma	0.000238	0.00427	CcSEcCtD
Canagliflozin—Constipation—Temozolomide—melanoma	0.000236	0.00423	CcSEcCtD
Canagliflozin—Asthenia—Bleomycin—melanoma	0.000235	0.00421	CcSEcCtD
Canagliflozin—Angiopathy—Docetaxel—melanoma	0.000234	0.00421	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Carmustine—melanoma	0.000233	0.00419	CcSEcCtD
Canagliflozin—Pruritus—Bleomycin—melanoma	0.000231	0.00415	CcSEcCtD
Canagliflozin—Abdominal pain—Carmustine—melanoma	0.000226	0.00405	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Temozolomide—melanoma	0.000226	0.00405	CcSEcCtD
Canagliflozin—Erythema—Docetaxel—melanoma	0.000225	0.00404	CcSEcCtD
Canagliflozin—Malnutrition—Docetaxel—melanoma	0.000225	0.00404	CcSEcCtD
Canagliflozin—Hypersensitivity—Dactinomycin—melanoma	0.000225	0.00403	CcSEcCtD
Canagliflozin—Urticaria—Temozolomide—melanoma	0.000219	0.00393	CcSEcCtD
Canagliflozin—Asthenia—Dactinomycin—melanoma	0.000219	0.00393	CcSEcCtD
Canagliflozin—Abdominal pain—Temozolomide—melanoma	0.000218	0.00391	CcSEcCtD
Canagliflozin—Hypersensitivity—Carmustine—melanoma	0.00021	0.00378	CcSEcCtD
Canagliflozin—Rash—Bleomycin—melanoma	0.000206	0.0037	CcSEcCtD
Canagliflozin—Dermatitis—Bleomycin—melanoma	0.000206	0.0037	CcSEcCtD
Canagliflozin—Asthenia—Carmustine—melanoma	0.000205	0.00368	CcSEcCtD
Canagliflozin—Hypersensitivity—Temozolomide—melanoma	0.000203	0.00365	CcSEcCtD
Canagliflozin—Syncope—Docetaxel—melanoma	0.000202	0.00362	CcSEcCtD
Canagliflozin—Asthenia—Temozolomide—melanoma	0.000198	0.00355	CcSEcCtD
Canagliflozin—Loss of consciousness—Docetaxel—melanoma	0.000198	0.00355	CcSEcCtD
Canagliflozin—Pruritus—Temozolomide—melanoma	0.000195	0.0035	CcSEcCtD
Canagliflozin—Convulsion—Docetaxel—melanoma	0.000195	0.0035	CcSEcCtD
Canagliflozin—Nausea—Bleomycin—melanoma	0.000194	0.00349	CcSEcCtD
Canagliflozin—Rash—Dactinomycin—melanoma	0.000192	0.00345	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.00019	0.00341	CcSEcCtD
Canagliflozin—Dizziness—Carmustine—melanoma	0.000189	0.00339	CcSEcCtD
Canagliflozin—Dry mouth—Docetaxel—melanoma	0.000187	0.00336	CcSEcCtD
Canagliflozin—Dizziness—Temozolomide—melanoma	0.000182	0.00327	CcSEcCtD
Canagliflozin—Infection—Docetaxel—melanoma	0.000182	0.00327	CcSEcCtD
Canagliflozin—Nausea—Dactinomycin—melanoma	0.000181	0.00325	CcSEcCtD
Canagliflozin—Shock—Docetaxel—melanoma	0.000181	0.00324	CcSEcCtD
Canagliflozin—Rash—Carmustine—melanoma	0.00018	0.00323	CcSEcCtD
Canagliflozin—Nervous system disorder—Docetaxel—melanoma	0.00018	0.00323	CcSEcCtD
Canagliflozin—Dermatitis—Carmustine—melanoma	0.00018	0.00323	CcSEcCtD
Canagliflozin—Skin disorder—Docetaxel—melanoma	0.000178	0.0032	CcSEcCtD
Canagliflozin—Rash—Temozolomide—melanoma	0.000174	0.00312	CcSEcCtD
Canagliflozin—Dermatitis—Temozolomide—melanoma	0.000174	0.00312	CcSEcCtD
Canagliflozin—Hypotension—Docetaxel—melanoma	0.000171	0.00308	CcSEcCtD
Canagliflozin—Nausea—Carmustine—melanoma	0.00017	0.00304	CcSEcCtD
Canagliflozin—Nausea—Temozolomide—melanoma	0.000164	0.00294	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Docetaxel—melanoma	0.000158	0.00284	CcSEcCtD
Canagliflozin—Fatigue—Docetaxel—melanoma	0.000158	0.00284	CcSEcCtD
Canagliflozin—Constipation—Docetaxel—melanoma	0.000157	0.00282	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Docetaxel—melanoma	0.00015	0.00269	CcSEcCtD
Canagliflozin—Abdominal pain—Docetaxel—melanoma	0.000145	0.0026	CcSEcCtD
Canagliflozin—Hypersensitivity—Docetaxel—melanoma	0.000135	0.00243	CcSEcCtD
Canagliflozin—Asthenia—Docetaxel—melanoma	0.000132	0.00236	CcSEcCtD
Canagliflozin—Pruritus—Docetaxel—melanoma	0.00013	0.00233	CcSEcCtD
Canagliflozin—Dizziness—Docetaxel—melanoma	0.000121	0.00218	CcSEcCtD
Canagliflozin—Rash—Docetaxel—melanoma	0.000116	0.00208	CcSEcCtD
Canagliflozin—Dermatitis—Docetaxel—melanoma	0.000116	0.00207	CcSEcCtD
Canagliflozin—Nausea—Docetaxel—melanoma	0.000109	0.00196	CcSEcCtD
Canagliflozin—SLC5A2—Disease—NRAS—melanoma	2.47e-05	0.000246	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—APC—melanoma	2.47e-05	0.000246	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—GNA11—melanoma	2.44e-05	0.000243	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—GAB2—melanoma	2.44e-05	0.000243	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EGF—melanoma	2.44e-05	0.000243	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PIK3CD—melanoma	2.38e-05	0.000237	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—VCAN—melanoma	2.38e-05	0.000236	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—MAPK3—melanoma	2.37e-05	0.000236	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—MAPK3—melanoma	2.37e-05	0.000236	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CYP17A1—melanoma	2.36e-05	0.000235	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—ALB—melanoma	2.35e-05	0.000234	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PTEN—melanoma	2.32e-05	0.000231	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PTEN—melanoma	2.32e-05	0.000231	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—MYC—melanoma	2.3e-05	0.000229	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—MYC—melanoma	2.3e-05	0.000229	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—melanoma	2.3e-05	0.000229	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—HDAC2—melanoma	2.3e-05	0.000229	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—IGF1—melanoma	2.3e-05	0.000229	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—GNAQ—melanoma	2.27e-05	0.000226	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—CD44—melanoma	2.27e-05	0.000226	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—ITGA4—melanoma	2.27e-05	0.000226	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—melanoma	2.26e-05	0.000225	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IFNB1—melanoma	2.26e-05	0.000225	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—MAPK1—melanoma	2.25e-05	0.000224	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—MAPK1—melanoma	2.25e-05	0.000224	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—EGFR—melanoma	2.25e-05	0.000224	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—EGFR—melanoma	2.25e-05	0.000224	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	2.25e-05	0.000224	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PLCB4—melanoma	2.22e-05	0.000221	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—AKT1—melanoma	2.21e-05	0.00022	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—PIK3CD—melanoma	2.21e-05	0.00022	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IFNA1—melanoma	2.2e-05	0.000219	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MAP2K1—melanoma	2.19e-05	0.000218	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—FASN—melanoma	2.18e-05	0.000217	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—melanoma	2.17e-05	0.000216	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—IL6—melanoma	2.17e-05	0.000216	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—SYK—melanoma	2.14e-05	0.000213	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—KRAS—melanoma	2.13e-05	0.000212	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—KRAS—melanoma	2.13e-05	0.000212	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—ITGAV—melanoma	2.1e-05	0.000209	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—AKT3—melanoma	2.1e-05	0.000209	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SLC6A11—melanoma	2.09e-05	0.000208	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIP4K2A—melanoma	2.09e-05	0.000208	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—FGF2—melanoma	2.08e-05	0.000207	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PIK3CB—melanoma	2.07e-05	0.000206	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PTGS2—melanoma	2.05e-05	0.000205	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IFNA2—melanoma	2.05e-05	0.000204	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—SLC5A5—melanoma	2.04e-05	0.000203	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—MTAP—melanoma	2.03e-05	0.000202	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CYP17A1—melanoma	2e-05	0.0002	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CYP1B1—melanoma	1.98e-05	0.000197	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	1.98e-05	0.000197	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—melanoma	1.97e-05	0.000197	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PIK3CA—melanoma	1.95e-05	0.000195	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PIK3CA—melanoma	1.95e-05	0.000195	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—ALB—melanoma	1.95e-05	0.000194	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—melanoma	1.95e-05	0.000194	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PLCB4—melanoma	1.94e-05	0.000194	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—PIK3CB—melanoma	1.92e-05	0.000191	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—melanoma	1.92e-05	0.000191	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—ITGB1—melanoma	1.9e-05	0.00019	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GNA11—melanoma	1.89e-05	0.000188	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—melanoma	1.88e-05	0.000187	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ACER3—melanoma	1.86e-05	0.000185	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—FASN—melanoma	1.85e-05	0.000184	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SLC6A11—melanoma	1.83e-05	0.000182	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIP4K2A—melanoma	1.83e-05	0.000182	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—SLC5A5—melanoma	1.82e-05	0.000181	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—ALB—melanoma	1.81e-05	0.00018	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PHGDH—melanoma	1.81e-05	0.00018	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—LUM—melanoma	1.81e-05	0.00018	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—HRAS—melanoma	1.81e-05	0.00018	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—HRAS—melanoma	1.81e-05	0.00018	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PTEN—melanoma	1.79e-05	0.000178	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—SLC5A5—melanoma	1.78e-05	0.000178	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—MTAP—melanoma	1.78e-05	0.000177	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—melanoma	1.78e-05	0.000177	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—HPSE—melanoma	1.77e-05	0.000177	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—IL2—melanoma	1.77e-05	0.000176	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GNAQ—melanoma	1.76e-05	0.000175	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CD44—melanoma	1.76e-05	0.000175	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—HGF—melanoma	1.74e-05	0.000173	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—melanoma	1.74e-05	0.000173	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CUBN—melanoma	1.74e-05	0.000173	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—IL6—melanoma	1.73e-05	0.000172	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—IL6—melanoma	1.73e-05	0.000172	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	1.72e-05	0.000172	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—CSF2—melanoma	1.72e-05	0.000171	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—melanoma	1.71e-05	0.00017	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—UGT2B10—melanoma	1.7e-05	0.000169	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—melanoma	1.69e-05	0.000169	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CYP1B1—melanoma	1.69e-05	0.000168	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SDHD—melanoma	1.68e-05	0.000167	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CSPG4—melanoma	1.68e-05	0.000167	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—BSG—melanoma	1.68e-05	0.000167	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—melanoma	1.68e-05	0.000167	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—ITGB3—melanoma	1.65e-05	0.000164	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PRKCA—melanoma	1.65e-05	0.000164	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—melanoma	1.64e-05	0.000163	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PIK3CA—melanoma	1.64e-05	0.000163	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PIK3CA—melanoma	1.64e-05	0.000163	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—melanoma	1.64e-05	0.000163	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GPAM—melanoma	1.63e-05	0.000162	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—melanoma	1.63e-05	0.000162	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—AKT1—melanoma	1.6e-05	0.000159	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—AKT1—melanoma	1.6e-05	0.000159	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PHGDH—melanoma	1.58e-05	0.000158	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—LUM—melanoma	1.58e-05	0.000158	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HS3ST5—melanoma	1.58e-05	0.000157	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—HPSE—melanoma	1.55e-05	0.000155	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—ABCB1—melanoma	1.55e-05	0.000155	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—RAC1—melanoma	1.53e-05	0.000152	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CUBN—melanoma	1.53e-05	0.000152	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—VEGFA—melanoma	1.5e-05	0.000149	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—melanoma	1.49e-05	0.000148	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—MMP1—melanoma	1.48e-05	0.000147	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—melanoma	1.48e-05	0.000147	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SDHD—melanoma	1.47e-05	0.000147	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CSPG4—melanoma	1.47e-05	0.000147	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—BSG—melanoma	1.47e-05	0.000147	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—CDK2—melanoma	1.45e-05	0.000145	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GPAM—melanoma	1.43e-05	0.000142	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—MAPK3—melanoma	1.42e-05	0.000141	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—melanoma	1.4e-05	0.000139	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ABCB1—melanoma	1.39e-05	0.000138	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PLA2G6—melanoma	1.38e-05	0.000138	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—melanoma	1.36e-05	0.000135	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—FN1—melanoma	1.35e-05	0.000135	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—MAPK1—melanoma	1.35e-05	0.000134	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—AKT1—melanoma	1.34e-05	0.000133	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—AKT1—melanoma	1.34e-05	0.000133	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—NOS2—melanoma	1.33e-05	0.000133	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—melanoma	1.33e-05	0.000132	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—melanoma	1.33e-05	0.000132	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CG—melanoma	1.29e-05	0.000129	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PRKCA—melanoma	1.28e-05	0.000127	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—EGF—melanoma	1.28e-05	0.000127	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ERCC2—melanoma	1.27e-05	0.000126	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—melanoma	1.27e-05	0.000126	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PIK3CA—melanoma	1.26e-05	0.000126	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—melanoma	1.26e-05	0.000125	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—VCAN—melanoma	1.24e-05	0.000124	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PLA2G6—melanoma	1.21e-05	0.000121	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PLCB4—melanoma	1.2e-05	0.000119	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IGF1—melanoma	1.18e-05	0.000118	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	1.18e-05	0.000117	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—PIK3CA—melanoma	1.17e-05	0.000117	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—melanoma	1.15e-05	0.000115	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CD—melanoma	1.14e-05	0.000113	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PPARG—melanoma	1.14e-05	0.000113	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIP4K2A—melanoma	1.13e-05	0.000112	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SLC6A11—melanoma	1.13e-05	0.000112	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—melanoma	1.12e-05	0.000111	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—MTAP—melanoma	1.1e-05	0.000109	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—VCAN—melanoma	1.09e-05	0.000108	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.05e-05	0.000105	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP17A1—melanoma	1.05e-05	0.000104	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	1.03e-05	0.000103	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—AKT1—melanoma	1.03e-05	0.000103	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CG—melanoma	1e-05	9.97e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GNA11—melanoma	9.91e-06	9.87e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CB—melanoma	9.91e-06	9.86e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—LUM—melanoma	9.76e-06	9.72e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PHGDH—melanoma	9.76e-06	9.72e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—FASN—melanoma	9.7e-06	9.65e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PPARG—melanoma	9.66e-06	9.62e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HPSE—melanoma	9.57e-06	9.53e-05	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—AKT1—melanoma	9.57e-06	9.53e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SLC5A5—melanoma	9.54e-06	9.5e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—melanoma	9.42e-06	9.38e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CUBN—melanoma	9.4e-06	9.36e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GNAQ—melanoma	9.21e-06	9.17e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CD44—melanoma	9.21e-06	9.17e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP17A1—melanoma	9.19e-06	9.15e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IL2—melanoma	9.1e-06	9.06e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—BSG—melanoma	9.07e-06	9.04e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SDHD—melanoma	9.07e-06	9.04e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CSPG4—melanoma	9.07e-06	9.04e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	9.02e-06	8.98e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PTGS2—melanoma	8.94e-06	8.9e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP1B1—melanoma	8.83e-06	8.79e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CD—melanoma	8.8e-06	8.76e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GPAM—melanoma	8.79e-06	8.75e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ALB—melanoma	8.69e-06	8.65e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GNA11—melanoma	8.68e-06	8.64e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—ALB—melanoma	8.51e-06	8.47e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—FASN—melanoma	8.5e-06	8.46e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SLC5A5—melanoma	8.36e-06	8.32e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GNAQ—melanoma	8.07e-06	8.04e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CD44—melanoma	8.07e-06	8.04e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PTEN—melanoma	7.79e-06	7.76e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP1B1—melanoma	7.74e-06	7.7e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—VEGFA—melanoma	7.73e-06	7.7e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CB—melanoma	7.67e-06	7.64e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—NRAS—melanoma	7.64e-06	7.61e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PTGS2—melanoma	7.6e-06	7.57e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PLA2G6—melanoma	7.47e-06	7.44e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—MAPK3—melanoma	7.31e-06	7.28e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ABCB1—melanoma	7.27e-06	7.24e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—MAPK1—melanoma	6.96e-06	6.93e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—VCAN—melanoma	6.71e-06	6.68e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PRKCA—melanoma	6.69e-06	6.66e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ERCC2—melanoma	6.64e-06	6.61e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PTEN—melanoma	6.63e-06	6.6e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—KRAS—melanoma	6.57e-06	6.55e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CA—melanoma	6.04e-06	6.01e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PRKCA—melanoma	5.86e-06	5.84e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TP53—melanoma	5.84e-06	5.82e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ERCC2—melanoma	5.82e-06	5.79e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP17A1—melanoma	5.66e-06	5.64e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—HRAS—melanoma	5.59e-06	5.56e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	5.5e-06	5.47e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GNA11—melanoma	5.35e-06	5.33e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CG—melanoma	5.24e-06	5.22e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—FASN—melanoma	5.23e-06	5.21e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SLC5A5—melanoma	5.15e-06	5.13e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PPARG—melanoma	5.06e-06	5.04e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GNAQ—melanoma	4.97e-06	4.95e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CD44—melanoma	4.97e-06	4.95e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—AKT1—melanoma	4.93e-06	4.91e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP1B1—melanoma	4.77e-06	4.75e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CA—melanoma	4.68e-06	4.66e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CD—melanoma	4.61e-06	4.59e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CG—melanoma	4.59e-06	4.57e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PPARG—melanoma	4.43e-06	4.41e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CD—melanoma	4.04e-06	4.02e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CB—melanoma	4.02e-06	4e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ALB—melanoma	3.99e-06	3.97e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PTGS2—melanoma	3.98e-06	3.96e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ABCB1—melanoma	3.93e-06	3.91e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—AKT1—melanoma	3.82e-06	3.8e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PRKCA—melanoma	3.61e-06	3.6e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ERCC2—melanoma	3.58e-06	3.57e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CB—melanoma	3.52e-06	3.5e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PTGS2—melanoma	3.49e-06	3.47e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PTEN—melanoma	3.47e-06	3.46e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PTEN—melanoma	3.04e-06	3.03e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CG—melanoma	2.83e-06	2.82e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PPARG—melanoma	2.73e-06	2.72e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CD—melanoma	2.49e-06	2.48e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ALB—melanoma	2.46e-06	2.45e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CA—melanoma	2.45e-06	2.44e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CB—melanoma	2.17e-06	2.16e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PTGS2—melanoma	2.15e-06	2.14e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CA—melanoma	2.15e-06	2.14e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—AKT1—melanoma	2e-06	1.99e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PTEN—melanoma	1.87e-06	1.87e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—AKT1—melanoma	1.75e-06	1.75e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CA—melanoma	1.32e-06	1.32e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—AKT1—melanoma	1.08e-06	1.08e-05	CbGpPWpGaD
